FUNCTIONAL FLUIDICS INC.
Grosse Pointe Park, MI · CIK 0001775306 · Medtech · Private
Tools and instruments to predict, select, and monitor red blood cell function
functionalfluidics.com →- Grants
- $1.1M
- 5 awards
- Sector median: 1
- Raised
- $1.9M
- 2 Form D · Jul 2020
- 74 months since last filing
- Contracts
- $100K
- 1 award · Health and Human S
- #517 of 4531 in medtech
- Patents
- 3
- 2 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | $224,512 | |
| Federal grant | Department of Health and Human Services · Phase I · Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | $224,512 | |
| Private capital raised | Form D · SEC | $150,000 | |
| Private capital raised | Form D · SEC | $1,725,625 | |
| Federal grant | Department of Health and Human Services · Phase I · Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | $168,087 | |
| Federal grant | Department of Health and Human Services · Phase I · Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | $168,087 | |
| Federal contract | Department of Health and Human Services · Rbc Health As A Novel Biomarker Of A Successful Outcome In Hematopoietic Stem Cell Transplantation (hsct) For Sickle Cell Disease (scd) | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of POC system for patient condition and treatment monitoring in Sickle Cell Disease through hypoxia-induced sickling | $265,347 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 514 | ALM Ortho Inc | $107K | $135K |
| 515 | INFINITE BIOMEDICAL TECHNOLOGIES, LLC | $105K | — |
| 516 | RETHINK MEDICAL, INC. | $104K | $3.2M |
| 517 | FUNCTIONAL FLUIDICS INC. | $100K | $1.9M |
| 518 | OmniScience LLC | $100K | — |
| 519 | ACTIVAS DIAGNOSTICS, LLC | $100K | — |
| 520 | TRIBOFILM RESEARCH INC | $100K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- John CunninghamExecutive Officer
- Patrick HinesDirector · Executive Officer
Patents
- System and Method for Assessing an Effect on Cellular Units in an Organismgranted
- Method for Assessing the Effects of Hypoxia on Tissuesapplication
- Method for Assessing the Effects of Hypoxia on Tissuesgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.